Education
About Us
Working with TipRanks
Follow Us
Amplia Therapeutics Ltd. (INNMF)
:INNMF
Total Valuation
Amplia Therapeutics has a market cap or net worth of $44.51M. The enterprise value is $9.50M.
Market Cap$44.51M
Enterprise Value$9.50M
Share Statistics
Amplia Therapeutics has 387,952,670 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding387,952,670
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Amplia Therapeutics’s return on equity (ROE) is -0.39 and return on invested capital (ROIC) is -17.13%.
Return on Equity (ROE)-0.39
Return on Assets (ROA)-0.30
Return on Invested Capital (ROIC)-17.13%
Return on Capital Employed (ROCE)-0.39
Revenue Per Employee4.45M
Profits Per Employee-4.50M
Employee Count1
Asset Turnover0.30
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Amplia Therapeutics is -3.22. Amplia Therapeutics’s PEG ratio is -0.09.
PE Ratio-3.22
PS Ratio0.00
PB Ratio1.04
Price to Fair Value1.27
Price to FCF-3.11
Price to Operating Cash Flow-3.12
PEG Ratio-0.09
Income Statement
In the last 12 months, Amplia Therapeutics had revenue of 4.45M and earned -4.50M in profits. Earnings per share was -0.02.
Revenue4.45M
Gross Profit4.01M
Operating Income-4.42M
Pretax Income-8.94M
Net Income-4.50M
EBITDA-4.56M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -2.76M and capital expenditures -2.62K, giving a free cash flow of -2.76M billion.
Operating Cash Flow-2.76M
Free Cash Flow-2.76M
Free Cash Flow per Share>-0.01
Dividends & Yields
Amplia Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-1.11
52-Week Price Change175.00%
50-Day Moving Average0.04
200-Day Moving Average0.06
Relative Strength Index (RSI)79.46
Average Volume (3m)21.75K
Important Dates
Amplia Therapeutics upcoming earnings date is Nov 27, 2025, TBA (Confirmed).
Last Earnings DateMay 30, 2025
Next Earnings DateNov 27, 2025
Ex-Dividend Date―
Financial Position
Amplia Therapeutics as a current ratio of 1.98, with Debt / Equity ratio of 14.33%
Current Ratio1.98
Quick Ratio1.98
Debt to Market Cap0.10
Net Debt to EBITDA0.39
Interest Coverage Ratio-56.38
Taxes
In the past 12 months, Amplia Therapeutics has paid -4.44M in taxes.
Income Tax-4.44M
Effective Tax Rate0.50
Enterprise Valuation
Amplia Therapeutics EV to EBITDA ratio is -2.79, with an EV/FCF ratio of -2.48.
EV to Sales2.86
EV to EBITDA-2.79
EV to Free Cash Flow-2.48
EV to Operating Cash Flow-2.48
Balance Sheet
Amplia Therapeutics has $4.56M in cash and marketable securities with AU$54.99K in debt, giving a net cash position of -$4.50M billion.
Cash & Marketable Securities$4.56M
Total DebtAU$54.99K
Net Cash-$4.50M
Net Cash Per Share-$0.01
Tangible Book Value Per Share$0.02
Margins
Gross margin is 93.83%, with operating margin of -99.38%, and net profit margin of -101.14%.
Gross Margin93.83%
Operating Margin-99.38%
Pretax Margin-200.80%
Net Profit Margin-101.14%
EBITDA Margin-102.40%
EBIT Margin-102.64%
Analyst Forecast
The average price target for Amplia Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―